Abstract
Shortening therapy duration with direct-acting antiviral agents (DAAs) is desirable to pursue the WHO target of HCV eradication by 2030. We report two cases of HCV-infected women who achieved sustained virologic response after an ultra-short treatment with glecaprevir/pibrentasvir (G/P), discontinued due to cutaneous adverse events, and analyze similar cases reported in the literature. Female gender seems to be a prevailing characteristic in this group of patients. G/P, due to its pangenotypic and strong antiviral activity, may represent a candidate for a shortened DAA regimen in non-cirrhotic treatment-naive subjects.
MeSH terms
-
Aminoisobutyric Acids* / therapeutic use
-
Anti-Retroviral Agents / therapeutic use
-
Antiviral Agents* / therapeutic use
-
Benzimidazoles* / therapeutic use
-
Cyclopropanes* / therapeutic use
-
Drug Combinations
-
Female
-
Hepatitis C, Chronic* / drug therapy
-
Humans
-
Lactams, Macrocyclic* / therapeutic use
-
Leucine / analogs & derivatives*
-
Leucine / therapeutic use
-
Proline / analogs & derivatives*
-
Proline / therapeutic use
-
Pyrrolidines* / therapeutic use
-
Quinoxalines* / therapeutic use
-
Sulfonamides* / therapeutic use
Substances
-
Aminoisobutyric Acids
-
Anti-Retroviral Agents
-
Antiviral Agents
-
Benzimidazoles
-
Cyclopropanes
-
Drug Combinations
-
Lactams, Macrocyclic
-
Pyrrolidines
-
Quinoxalines
-
Sulfonamides
-
pibrentasvir
-
Proline
-
Leucine
-
glecaprevir